Journal Scan

Can an Immunotherapy Combination Improve Outcomes in Patients With Melanoma Metastatic to the Brain?

Posted on

Approximately 75% of patients with melanoma develop brain metastases before death, which has an extremely poor progonosis (median overall survival, 4-5 mo). The phase 2 CheckMate 204 trial recently published data that showed combining the CTLA4 inhibitor ipilimumab (Yervoy) with the PD-1 inhibitor nivolumab (Opdivo) can arrest or shrink brain tumors in many patients. Findings were reported for 94 patients with stage 4 melanoma who were followed for a median of 14 months. The intracranial benefit rate was 57%, calculated by combining rates of intracranial complete response (26%), partial response (30%), and stable disease (2%). At 9 months follow-up, 60% of patients had experienced no brain tumor progression, and 83% of patients were still alive.

Read more here.


Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722-730. doi: 10.1056/NEJMoa1805453.

Related Articles
Liver Cancer Rates Increase in Developed Countries
May 18, 2020
Rare Disease Day: Get to Know About Sarcoma
Mar 27, 2020
ASCO Cancels Annual Meeting, Switches to Virtual Format
Mar 25, 2020